ARTL

Artelo Biosciences, Inc.

1.53 USD
+0.11 (+7.75%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Artelo Biosciences, Inc. stock is up 15.91% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 May’s closed higher than April.

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc. focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer. ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD.